NO20081727L - Behandling av autoimmune sykdommer - Google Patents

Behandling av autoimmune sykdommer

Info

Publication number
NO20081727L
NO20081727L NO20081727A NO20081727A NO20081727L NO 20081727 L NO20081727 L NO 20081727L NO 20081727 A NO20081727 A NO 20081727A NO 20081727 A NO20081727 A NO 20081727A NO 20081727 L NO20081727 L NO 20081727L
Authority
NO
Norway
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
methods
Prior art date
Application number
NO20081727A
Other languages
English (en)
Norwegian (no)
Inventor
Rainer Albert
Nigel Graham Cooke
Sven Weiler
Barbara Nuesslein-Hildesheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081727L publication Critical patent/NO20081727L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20081727A 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer NO20081727L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
PCT/EP2006/066150 WO2007028821A2 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
NO20081727L true NO20081727L (no) 2008-06-06

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081727A NO20081727L (no) 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer

Country Status (28)

Country Link
US (1) US20080200438A1 (es)
EP (2) EP1926483B1 (es)
JP (4) JP5244598B2 (es)
KR (3) KR101476591B1 (es)
CN (1) CN101257899B (es)
AT (1) ATE489948T1 (es)
AU (2) AU2006289100B2 (es)
BR (1) BRPI0615906A2 (es)
CA (2) CA2820510A1 (es)
CY (1) CY1111285T1 (es)
DE (1) DE602006018629D1 (es)
DK (2) DK1926483T3 (es)
ES (2) ES2529724T3 (es)
IL (2) IL189665A (es)
JO (1) JO2655B1 (es)
MA (1) MA29787B1 (es)
MX (1) MX2008003170A (es)
NO (1) NO20081727L (es)
NZ (2) NZ588372A (es)
PL (2) PL1926483T3 (es)
PT (2) PT2295049E (es)
RU (2) RU2424795C2 (es)
SG (1) SG165364A1 (es)
SI (2) SI2295049T1 (es)
TN (1) TNSN08103A1 (es)
TW (2) TWI372620B (es)
WO (1) WO2007028821A2 (es)
ZA (1) ZA200801694B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
AU2005292984B2 (en) 2004-10-12 2011-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same
RU2421214C2 (ru) * 2005-10-07 2011-06-20 Киорин Фармасьютикал Ко., Лтд. Терапевтическое средство для лечения гепатита и способ лечения гепатита
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US8232319B2 (en) * 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
EP2305305A4 (en) * 2008-05-20 2013-02-13 Kyorin Seiyaku Kk MEDIUM FOR INTRODUCTION / MAINTENANCE OF THE REMISSION
CA2734585A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
NZ603999A (en) * 2010-05-06 2014-06-27 Novartis Ag Treatment of autoimmune diseases
AU2011249789B2 (en) * 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003264430B2 (en) * 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
MXPA05003254A (es) * 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
KR100995486B1 (ko) * 2002-09-28 2010-11-22 맥네일-피피씨, 인코포레이티드 개구가 있는 쉘을 포함하는 속방성 투여형
DK1602660T3 (da) 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
DE202004021680U1 (de) * 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
MXPA06002349A (es) * 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MX2008003170A (es) 2008-03-18
JP6077265B2 (ja) 2017-02-08
KR20140117704A (ko) 2014-10-07
IL189665A (en) 2014-07-31
CY1111285T1 (el) 2015-08-05
SI2295049T1 (sl) 2015-03-31
KR20080046231A (ko) 2008-05-26
HK1149906A1 (en) 2011-10-21
DK2295049T3 (en) 2015-02-23
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
JP2013010802A (ja) 2013-01-17
CA2620554A1 (en) 2007-03-15
EP1926483A2 (en) 2008-06-04
PL1926483T3 (pl) 2011-05-31
RU2424795C2 (ru) 2011-07-27
JO2655B1 (en) 2012-06-17
TW200803829A (en) 2008-01-16
AU2006289100A1 (en) 2007-03-15
IL233328A0 (en) 2014-08-31
CN101257899A (zh) 2008-09-03
PT1926483E (pt) 2011-03-03
AU2010224355B2 (en) 2012-03-29
EP1926483B1 (en) 2010-12-01
KR20140019033A (ko) 2014-02-13
IL189665A0 (en) 2008-06-05
PT2295049E (pt) 2015-03-02
TWI376223B (en) 2012-11-11
CA2620554C (en) 2013-12-17
TNSN08103A1 (en) 2009-07-14
KR101476451B1 (ko) 2014-12-24
RU2011111117A (ru) 2012-09-27
RU2493840C2 (ru) 2013-09-27
EP2295049A1 (en) 2011-03-16
BRPI0615906A2 (pt) 2011-05-31
CA2820510A1 (en) 2007-03-15
SI1926483T1 (sl) 2011-04-29
SG165364A1 (en) 2010-10-28
CN101257899B (zh) 2012-10-03
ES2357426T3 (es) 2011-04-26
NZ588372A (en) 2012-03-30
TWI372620B (en) 2012-09-21
NZ566137A (en) 2011-05-27
JP2017019854A (ja) 2017-01-26
DK1926483T3 (da) 2011-03-14
JP2009507810A (ja) 2009-02-26
ATE489948T1 (de) 2010-12-15
EP2295049B1 (en) 2014-11-26
RU2008113187A (ru) 2009-10-20
JP5244598B2 (ja) 2013-07-24
AU2010224355A1 (en) 2010-10-14
AU2006289100B2 (en) 2010-07-22
WO2007028821A3 (en) 2007-05-03
ZA200801694B (en) 2009-09-30
WO2007028821A2 (en) 2007-03-15
MA29787B1 (fr) 2008-09-01
TW201034659A (en) 2010-10-01
JP2015025002A (ja) 2015-02-05
DE602006018629D1 (de) 2011-01-13
ES2529724T3 (es) 2015-02-25
PL2295049T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
TNSN08103A1 (en) Treatment of autoimmune diseases
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
EA201070247A1 (ru) Ингибиторы протеасом
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20076401L (no) Diarylhydantoinforbindelser
MX2009011210A (es) Inhibidores de mcl1 de indol 7-no sustituido.
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
UA85559C2 (en) Aminobenzophenone compounds
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
NO20080318L (no) Anvendelse av enkelt dose av CD-20-spesifikke bindingsmolekyler
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
NO20075706L (no) Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
NO20075370L (no) Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
NZ590276A (en) Use of nifurtimox for treating giardiasis
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application